This article is more than 5 years old. Information may no longer be current.
AbbVie finds success treating hidradenitis suppurativa with Humira
Click Here to Manage Email Alerts
AbbVie announced positive results from its phase 3 study of Humira for the treatment of hidradenitis suppurativa at the 44th Annual European Society for Dermatological Research Meeting, according to a company press release.
In the PIONEER I study, patients with moderate-to-severe hidradenitis suppurativa (HS) who were treated with Humira (adalimumab) 40 mg weekly achieved a significantly greater response compared with those on placebo at week 12 (41.8% vs. 26%, respectively). For the purposes of the study, the company defined a response as an improvement of HS-related abscesses and inflammatory nodules at week 12 using the Hidradenitis Suppurativa Clinical Response measure, which was marked by an at least 50% reduction in total abscess and inflammatory nodule count from baseline with no increase for either abscess or draining fistula count, according to the release.
AbbVie plans to present data from a second phase 3 study evaluating the safety and efficacy of HUMIRA in patients with moderate-to-severe HS, called PIONEER II, at an upcoming medical conference.
More information on the PIONEER I and PIONEER II studies is available at www.cliniclatrials.gov.